What the FDA labels say about taking them together
Cobicistat and etravirine
Cobicistat's FDA label of February 10, 2026 names etravirine in its drug interactions section, and etravirine's label names cobicistat too. The cobicistat label: “Coadministration with etravirine is not recommended because it may result in the loss of therapeutic effect and development of resistance to atazanavir or darunavir.”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the etravirine FDA label on DailyMed (effective August 15, 2023, Janssen Products LP).
What does the cobicistat label say about etravirine?
Cobicistat label, drug interactionsConcomitant Drug Class/Drug Name: etravirine; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↓ cobicistat darunavir: effect unknown ↓ atazanavir; Clinical Comment: Coadministration with etravirine is not recommended because it may result in the loss of therapeutic effect and development of resistance to atazanavir or darunavir.
Cobicistat label, warnings and precautionsMore than one antiretroviral that requires pharmacokinetic enhancement (i.e., two protease inhibitors or a protease inhibitor in combination with elvitegravir) Darunavir in combination with efavirenz, nevirapine, or etravirine Atazanavir in combination with etravirine Atazanavir in combination with efavirenz in treatment-experienced patients Darunavir 600 mg twice daily Other HIV-1 protease inhibitors including fosamprenavir, saquinavir, or tipranavir TYBOST in combination with fixed-dose combination tablets that contain cobicistat is not recommended.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the etravirine label say about cobicistat?
Etravirine label, drug interactionsConcomitant Drug Class/Drug Name: atazanavir/cobicistat; Effect on Concentration of Etravirine or Concomitant Drug: ↓ atazanavir ↓ cobicistat; Clinical Comment: Co-administration of INTELENCE with atazanavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to atazanavir.
Source: FDA drug label (Intelence), Janssen Products LP, effective August 15, 2023 (SPL set 6a9cbc29-9f15-4b24-8d86-206b82887f3d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Etravirine | |
|---|---|---|
| Labeled for | HIV | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $9.94 per tablet 200 mg tablet |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once